ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

EKF Ekf Diagnostics Holdings Plc

26.80
0.00 (0.00%)
Last Updated: 08:00:01
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 26.80 26.20 27.40 - 16,792 08:00:01
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Med, Dental, Hosp Eq-whsl 66.64M -10.1M -0.0222 -12.07 121.92M
Ekf Diagnostics Holdings Plc is listed in the Med, Dental, Hosp Eq-whsl sector of the London Stock Exchange with ticker EKF. The last closing price for Ekf Diagnostics was 26.80p. Over the last year, Ekf Diagnostics shares have traded in a share price range of 22.50p to 37.50p.

Ekf Diagnostics currently has 454,930,564 shares in issue. The market capitalisation of Ekf Diagnostics is £121.92 million. Ekf Diagnostics has a price to earnings ratio (PE ratio) of -12.07.

Ekf Diagnostics Share Discussion Threads

Showing 4826 to 4847 of 4850 messages
Chat Pages: 194  193  192  191  190  189  188  187  186  185  184  183  Older
DateSubjectAuthorDiscuss
27/3/2024
09:14
Two paragraphs added to the header, as I wanted to make sure that the 'precision fermentation' aspect was effectively highlighted and appreciated, as news here and elsewhere will likely feature going forwards. Including, a new EKF website that's scheduled for launch in the second quarter that will better reflect the dynamic global business, and better reflecting the cutting edge nature of EKF's Life Sciences and the global nature of EKF's Point-of-Care division:-

EKF Life Sciences is at the forefront of supporting global demand in precision fermentation, enzyme applications and research, providing innovative biotechnology solutions to deliver advancements in healthcare and medicine.

Utilising its unique technical expertise, EKF Life Sciences uses precision microbial fermentation and advanced downstream processes to isolate and deliver the highest quality enzymes and biomolecules that have been specially engineered to customer specifications.

wan
27/3/2024
05:39
Robow...It's certain funds associated to CM that have acquired over 132m shares, so it's unlikely to be their first purchase (or maybe even their last).

Pugugly...My thoughts are that EKF's current undervaluation may not go unnoticed, and CM would hopefully help thwart any low offers, even one at a 30% premium to todays price!

On the other hand, as EKF's highly cash generative Point-of-Care division returns to routine profitable growth this year, and Life Science scales up through 2024 and into 2025, CM's funds may support the right offer if it was at a significant premium to a recovered share price.

My preference is for EKF to continue growing, the Life Science division has a lot of exciting high growth opportunities to fulfil in 2024 and 2025 (and certain funds connected to Christopher Mills no doubt appreciate that).

wan
26/3/2024
21:35
Wan - Thanks. Interesting - Not yet enough to require an offer but (imo) enough to block a vulture bid. Thoughts?

"Under the Takeover Code, when a buyer acquires “control” of a target company it must make a cash offer to all shareholders offering to acquire their shares at the highest price paid in the last 12 months. The Takeover Code deems “control” of a target to arise when a buyer acquires shares carrying 30% or more of the voting rights."

An offer under Rule 9 must be made in cash and at the highest price paid by the person required to make the offer, or any person acting in concert with that person, for any interest in shares of the company during the 12 months prior to the announcement of the offer.

pugugly
26/3/2024
16:46
Well spotted Wan. Is this his first purchase?
robow
26/3/2024
05:05
In case anyone missed or misses it, EKF RNS after the market close (5.15pm) -

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that the Board of EKF has been informed that on Friday 22 March 2024, certain funds connected to Christopher Mills, Non-Executive Director, purchased a total of 100,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 25.78 pence per Ordinary Share.

Following this transaction, Christopher Mills' total direct and indirect interest in the Company is 132,350,000 Ordinary Shares, representing approximately 29.169% of the total voting rights over the Company's issued share capital.

wan
24/3/2024
08:48
Much appreciated.
pugugly
24/3/2024
08:00
Given that EKF's senior management team has successfully refocused the business back to pre-pandemic levels, and simplified the business by removing non-core, low-margin products from EKF's portfolio, which will result in increased profitability, it's worth looking at a few more comparisons from 2019 prior to the pandemic.

Towards the close of 2019 (prior to any effects of Covid), EKF shares were trading close to 35p

2019 Financial Highlights
• Revenue up 6% to £44.9m (2018: £42.5m)
• Gross profit up 4% to £23.7m (2018: £22.7m)
• Gross margin 52.8%
• Adjusted EBITDA* up 12% to £12.0m (2018: £10.7m)
• Profit before tax £5.5m
• Basic Earnings per share of 0.81p (2018: 2.21p), underlying Basic Earnings per share* of 1.20p (2018: 1.01p)
• Cash generated from operations of £6.5m (2018: £9.9m)
• Cash at 31 December 2019 of £12.1m (2018: £10.3m), net cash of £11.4m (2018: £9.4m)

2019 Analysers Sold - 14,167
2019 Tests Sold - 74,139,615


March 2024 Shares currently trading at around 26p

2023 Financial highlights
● Revenues of £52.6m in-line with market expectations (2022: £66.6m)
- Revenues (excluding COVID-related & clinical chemistry sales) of £48.7m (2022: £48.6m)

● Gross profit before exceptionals of £24.4m (2022: £30.8m)

● Gross margin improved to 45% (2022: 36%) and admin expenses reduced by £3.5m

● Adjusted EBITDA* of £10.4m (2022: £14.9m)

● A return to profit before tax of £2.1m (2022: loss of £8.9m)

● Cash generated from operations of £8.8m (2022: £12.7m)

● Group cash, net of borrowings (excluding IFRS 16 liabilities), at year end of £4.7m (2022: £11.4m), primarily reflecting cash generated from operations less £6.8m capital expenditure (2022: £4.4m) and £5.4m dividend payment (2022: £5.5m)

2023 Analysers Sold - 12,000+
2023 Tests Sold - 95 million+

In my view, this perhaps effectively demonstrates why Panmure Gordon says EKF looks circa 30% undervalued on the basis of the point of care division alone, which in turn implies a share price closer to 36p and is relatively achievable in the near term, if not already justifiable.

wan
23/3/2024
09:37
Thanks Wan!
cambridgedon
23/3/2024
09:19
As promised, I have created a new EKF thread which, as a consequence of notable investment, hard work, and the resulting developments delivered by the management, hopefully better represents where EKF is now and importantly where EKF is potentially heading.
wan
23/3/2024
09:18
As promised, I have created a new EKF thread which, as a consequence of notable investment, hard work, and the resulting developments delivered by the management, hopefully better represents where EKF is now and importantly where EKF is potentially heading -
wan
23/3/2024
09:07
EKF is a global diagnostics and biotechnology company delivers diagnostic technologies and biotechnology solutions that empower healthcare and medical providers to make informed clinical decisions through point-of-care testing and life sciences applications.

After rationalisations and investments made over the last two years resulting in a simplified structure of two divisions, Point-of-Care and Life Sciences, EKF is now well placed to deliver sustainable growth and improved returns.

In a buy recommended brokers note, Panmure Gordon said:
“EKF looks circa 30% undervalued on the basis of the point of care division alone, encouraging progress with customers in the new fermentation facility offers the potential for further upside. Emerging from its transitional period EKF is well positioned for a return to more consistent performance and a strengthening cash position.”


Singer Capital Markets broker note:
EKF’s FY23 results are in line / slightly ahead of expectations. Growth drivers remain intact in both Point-of-Care and Life Sciences and, with a greater focus on core products, margins should continue to improve from here. This is key to supporting a re-rating and we see considerable value at current levels. With profit forecasts unchanged, we roll forwards our valuation to FY24 and increase our TP to 36p, reiterating our Buy recommendation.
(full note available via Research Tree -

It's perhaps somewhat underappreciated that EKF has a well-established and comprehensive base of installed Point-of-Care diagnostic users supported by high-quality global distribution channels. In 2023, EKF sold over 12,000 Point-of-Care analysers, resulting in the sale and manufacture of over 95 million individual test consumables. The installed base of diagnostic instruments is currently delivering guaranteed recurring revenues of £35-40m, and is set for further growth in 2024 and beyond (cue Panmure Gordon's point-of-care comment above).

In Life Sciences, EKF has invested in a new facility with a full range of fermenters of different capacity, including increased downstream processing, offering contract fermentation services for clinically important enzymes and proteins.

EKF Life Sciences is at the forefront of supporting global demand in precision fermentation, enzyme applications and research, providing innovative biotechnology solutions to deliver advancements in healthcare and medicine.

Utilising its unique technical expertise, EKF Life Sciences uses precision microbial fermentation and advanced downstream processes to isolate and deliver the highest quality enzymes and biomolecules that have been specially engineered to customer specifications.

Customer onboarding has commenced with several fermentation runs completed that will generate revenue in 2024 and will lead to further growth in 2024 as the new customers scale up.

With a full range of fermenters of different capacity now online, EKF will look to scale up output throughout 2024 and to add additional customers throughout the current year.

EKF are also in active discussions with new fermentation customers for development and scale-up opportunities to come on-line late 2024 and through to 2025.

EKF's Outlook Statement:
• Investment in our focused core products within Hematology, Diabetes and β-HB will drive further, sustainable growth
• Strengthening relationships with key global partners and distribution channels to increase our existing market share in identified core product ranges
• 2024 will see the completion of the rationalisation process, resulting in a streamlined core business portfolio, and expansion of fermentation offering
• EKF is well placed to deliver growth and improved returns from the investments made over the last two years
Presentation -

Please conduct your own research when making investment decisions, as the originator, or the threads contributors, could be either wrong or inaccurate.

wan
21/3/2024
16:44
I don’t know tongosti. I only got in at the 27p level. Obviously that was the Covid periods lot of companies suffered then and Bailes was brought back in to sort it out. Time will tell as they say. This is probably the worst market in living memory without crashes. We have them daily now!
earwacks
21/3/2024
14:36
Clearly most of us would have been better off putting our money under the mattress or simply spending it on something nice!Lol. 3 years and counting but you've finally come around my good man!
tongosti
21/3/2024
14:35
Listen to Chris MillsIs this the same fella who was also bullish at 80p level? Just checking. Ta
tongosti
21/3/2024
08:18
Clearly most of us would have been better off putting our money under the mattress or simply spending it on something nice!

Moving on.....As the title of the thread and its contents are now well and truly out of date, I will create a new thread.

The new thread will be tightly focused on the areas of growth, and importantly the delivery of that growth as nothing else will matter!

In the interim, EKF's shares look considerably undervalued, but the market is clearly not impressed with either the results nor presumably the immediate outlook.

The market will continue to be unforgiving of any further delays or misses, but with a backdrop of falling interest rates, and on the basis of the management delivering good rates of cash generation and growth against a lowly rated share price, the share price performance from here could more than offset the dividend loss....and it needs to, otherwise why are we even here!

wan
20/3/2024
20:59
We certainly have had a good kicking over the last period and punished today.I'm hoping all the rubbish is out there now and we can build back up. The cost cutting has yielded monetary benefits but probably also weakened the business from a knowledge aspect and doesn't give obvious allowance for growth.If this new facility and capacity gets utilised and quickly, (this year unlikely but let's dream) the share price reversal could be quite dramatic.On a positive, it does look as though they are back in control but they really do need to speed up and step up monetising their assets after all this investment and time has been sunk into it.No more delays please...
hopeful holder
20/3/2024
14:57
Don't know where you get your "30% below fair value" from? On an EV/EBITDA and p/e basis they look pricey to me. Little to no growth from either point-of-care or life sciences. Finally, revenues and profits from the new fermentation facility being pushed out to the right.
redwing1
20/3/2024
09:42
Fair point on the enzyme business. It wasn’t expected but that still leaves the current business about 30 percent below fair value for a solid growth company restructured and returning to profitability. In previous years potential stories were a big part of the share price. Right at the end of chair’s statement he talks about scalability of enzyme by 2026. Should be more on that in presentation.At the moment most stock seem to be receiving luke warm reception to pretty decent results under the most trying times in living memory
earwacks
20/3/2024
09:30
To be fair there doesn't seem to have been much progress on the game changing enzyme business since September.
comsack
20/3/2024
09:24
36p without the game changing enzyme business, typically ignored by the markets the uk is undoubtedly the worst market to invest, all largely thanks to the ridiculous Brexit saga. Will we ever recover or just wait for all the best stock to get bought out by other counties. Seems to be the only game left
earwacks
20/3/2024
08:53
Broker note -

EKF’s FY23 results are in line / slightly ahead of expectations. Growth drivers remain intact in both Point-of-Care and Life Sciences and, with a greater focus on core products, margins should continue to improve from here. This is key to supporting a re-rating and we see considerable value at current levels. With profit forecasts unchanged, we roll forwards our valuation to FY24 and increase our TP to 36p, reiterating our Buy recommendation.

wan
19/3/2024
13:56
Wan my good man - will you ever learn?!
tongosti
Chat Pages: 194  193  192  191  190  189  188  187  186  185  184  183  Older

Your Recent History

Delayed Upgrade Clock